Efficacy and tolerability of zolmitriptan oro-dispersible wafer in treatment of childhood migraine

Kerrison, Caroline, Wright, Francesca, Piper, Joseph, Kumar, Ram and Hawcutt, Daniel B ORCID: 0000-0002-8120-6507 (2014) Efficacy and tolerability of zolmitriptan oro-dispersible wafer in treatment of childhood migraine EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 21 (2). pp. 84-86. ISSN 2047-9956, 2047-9964

Text Zolmitriptan manuscript v5.0.doc - Unspecified Download (113kB)

Abstract

Introduction Migraine affects 8% of children, and may require pharmacological therapy to control symptoms. Current acute treatments include (5-Hydroxytryptamine Receptor 1 (5-HT<inf>1</inf>) receptor agonists, although the only licensed medication for paediatric patients in this class in the UK is intranasal sumatriptan. Oro-dispersible wafers of zolmitriptan are used in practice but have not been evaluated in the paediatric setting. Methods A prospective case note audit of orodispersible zolmitriptan wafers use in the treatment of paediatric migraine by a consultant paediatric neurologist was carried out. Results Symptomatic benefit was noted in 71.4% (n=10) of patients who have been prescribed the orodispersible wafer formulation. All subgroups of migraine included in the audit had some participants who benefitted from the medication. Five patients (35.7%) complained of mild adverse effects: nausea (n=2, 14.3%); Somnolence (n=2, 14.3%); Tingling sensation on the tongue (n=1, 7.1%). No patients had any severe adverse effects. Conclusions In children with migraine treated in a tertiary paediatric neurology setting, the oro-dispersible wafer formulation of zolmitriptan is effective and well tolerated. Adequately powered prospective studies are required to determine the optimal place for this medication in paediatric migraine management.

Item Type:	Article
Additional Information:	## TULIP Type: Articles/Papers (Journal) ##
Uncontrolled Keywords:	3214 Pharmacology and Pharmaceutical Sciences, 32 Biomedical and Clinical Sciences, Patient Safety, Migraines, Pediatric Research Initiative, Chronic Pain, Headaches, Neurosciences, Pain Research, Brain Disorders, 6.1 Pharmaceuticals
Subjects:	?? RJ101 ?? ?? RM ?? ?? RS ??
Depositing User:	Symplectic Admin
Date Deposited:	08 Jan 2016 11:48
Last Modified:	16 Jun 2026 12:15
DOI:	10.1136/ejhpharm-2013-000347
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/2045339
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.